DK3400217T3 - L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf - Google Patents

L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf Download PDF

Info

Publication number
DK3400217T3
DK3400217T3 DK17700392.8T DK17700392T DK3400217T3 DK 3400217 T3 DK3400217 T3 DK 3400217T3 DK 17700392 T DK17700392 T DK 17700392T DK 3400217 T3 DK3400217 T3 DK 3400217T3
Authority
DK
Denmark
Prior art keywords
valinate
salt
crystal form
carboxamide derivatives
hydroxypropylthiazolidine
Prior art date
Application number
DK17700392.8T
Other languages
English (en)
Inventor
Page Patrick Naxos
Matthias Schwarz
Catherine Jorand-Lebrun
Vincent Pomel
Anna Quattropani
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/987,586 external-priority patent/US9447055B1/en
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of DK3400217T3 publication Critical patent/DK3400217T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Emergency Medicine (AREA)
DK17700392.8T 2016-01-04 2017-01-04 L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf DK3400217T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662274674P 2016-01-04 2016-01-04
US14/987,586 US9447055B1 (en) 2016-01-04 2016-01-04 α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US201662395664P 2016-09-16 2016-09-16
US201662407918P 2016-10-13 2016-10-13
PCT/EP2017/050101 WO2017118641A1 (en) 2016-01-04 2017-01-04 L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

Publications (1)

Publication Number Publication Date
DK3400217T3 true DK3400217T3 (da) 2022-06-07

Family

ID=57799697

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17700392.8T DK3400217T3 (da) 2016-01-04 2017-01-04 L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf
DK17700391.0T DK3397622T3 (en) 2016-01-04 2017-01-04 Co-administration af alpha-aminoester af hydroxypropylthiazolidincarboxamid-derivat og et tokolytisk middel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17700391.0T DK3397622T3 (en) 2016-01-04 2017-01-04 Co-administration af alpha-aminoester af hydroxypropylthiazolidincarboxamid-derivat og et tokolytisk middel

Country Status (23)

Country Link
EP (4) EP4144351A1 (da)
JP (5) JP6933322B2 (da)
KR (2) KR20180099708A (da)
CN (1) CN108779087A (da)
AU (4) AU2017205670B2 (da)
CA (2) CA3009573A1 (da)
DK (2) DK3400217T3 (da)
EA (1) EA036990B1 (da)
ES (2) ES2916835T3 (da)
HR (2) HRP20220674T1 (da)
HU (2) HUE058871T2 (da)
IL (4) IL284912B (da)
LT (2) LT3397622T (da)
MA (2) MA43580A (da)
MX (3) MX2018008304A (da)
PL (2) PL3400217T3 (da)
PT (2) PT3397622T (da)
RS (2) RS63286B1 (da)
SG (4) SG11201804789QA (da)
SI (2) SI3400217T1 (da)
UA (2) UA125377C2 (da)
WO (2) WO2017118641A1 (da)
ZA (1) ZA201903769B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL284912B (en) * 2016-01-04 2022-07-01 Merck Serono Sa L-Valinate derivative of hydroxypropylthiazolidine carboxamide and salt form, crystalline polymorph thereof
RU2711615C1 (ru) * 2019-09-12 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения эндометриоза на основании экспериментальной модели у крыс
EP4034129A4 (en) * 2019-09-23 2023-11-01 The Board of Trustees of the Leland Stanford Junior University TREATMENT PROCEDURES FOR GESTATIONAL EXTENSION AND FOR MENSTRUAL OR GESTATIONAL COMPLICATIONS

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835175A (en) 1971-03-15 1974-09-10 Research Corp 9-fluorenylmethanol haloformates, carbonates and thiocarbonates
US3839396A (en) 1971-07-15 1974-10-01 Shionogi & Co 9-lower alkyl-9-fluorenyl carbonates
US4108846A (en) 1977-02-01 1978-08-22 Hoffmann-La Roche Inc. Solid phase synthesis with base N alpha-protecting group cleavage
SE430885B (sv) 1980-03-24 1983-12-19 Ferring Ab Oxytocin-derivat
US4508657A (en) 1982-01-19 1985-04-02 Research Corporation Peptide synthesis and amino acid blocking agents
US4581167A (en) 1982-01-19 1986-04-08 Research Corporation Peptide synthesis and amino acid blocking agents
EP0112809B1 (en) 1982-12-21 1986-05-28 Ferring AB Vasotocin derivatives
US4460501A (en) 1983-08-30 1984-07-17 Research Corporation Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy
DE4434488A1 (de) * 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
IN188411B (da) * 1997-03-27 2002-09-21 Yuhan Corp
AU2001261161A1 (en) * 2000-05-30 2001-12-11 Ortho-Mcneil Pharmaceutical, Inc. Dihydropyridine compounds for inhibition of calcium-influx
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
ES2277640T3 (es) 2002-02-27 2007-07-16 Ferring Bv Productos intermedios y metodos para preparar analogos de heptapeptido de oxitocina.
UA78021C2 (en) * 2002-03-28 2007-02-15 Applied Research Systems Thiazolidine carboxamide derivatives as modulators of prostaglandine f receptors
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
AU2003300901A1 (en) * 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
WO2011051814A1 (en) 2009-10-30 2011-05-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
WO2015192878A1 (en) 2014-06-16 2015-12-23 Glaxosmithkline Intellectual Property Development Limited Retosiban for the treatment of pre-term labour
CN106795110A (zh) 2014-07-02 2017-05-31 奥布赛瓦股份公司 治疗ot‑r活性相关的病症的方法中可用的晶体(3z,5s)‑5‑(羟甲基)‑1‑[(2’‑甲基‑1,1’‑联苯‑4‑基)羰基]吡咯烷‑3‑酮o‑甲基肟
EP3037101B1 (en) 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
IL284912B (en) 2016-01-04 2022-07-01 Merck Serono Sa L-Valinate derivative of hydroxypropylthiazolidine carboxamide and salt form, crystalline polymorph thereof
US9447055B1 (en) * 2016-01-04 2016-09-20 Merck Serono S.A. α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

Also Published As

Publication number Publication date
EP3400217B1 (en) 2022-03-09
PL3400217T3 (pl) 2022-07-04
HUE058872T2 (hu) 2022-09-28
AU2021218003A1 (en) 2021-09-02
IL260286B (en) 2022-02-01
ES2915948T3 (es) 2022-06-27
MX2018008157A (es) 2018-09-03
KR20180099708A (ko) 2018-09-05
JP2019501897A (ja) 2019-01-24
IL289256A (en) 2022-02-01
UA125118C2 (uk) 2022-01-12
JP2023002668A (ja) 2023-01-10
LT3397622T (lt) 2022-06-27
ZA201903769B (en) 2023-03-29
AU2021218009A1 (en) 2021-09-09
JP7432284B2 (ja) 2024-02-16
EA036990B1 (ru) 2021-01-25
CN108779087A (zh) 2018-11-09
WO2017118639A1 (en) 2017-07-13
WO2017118641A1 (en) 2017-07-13
AU2017205670A1 (en) 2018-08-16
JP2019500351A (ja) 2019-01-10
SG11201804594YA (en) 2018-06-28
JP2024012376A (ja) 2024-01-30
AU2023233151A1 (en) 2023-10-12
SG10202009723PA (en) 2020-11-27
KR20180100120A (ko) 2018-09-07
LT3400217T (lt) 2022-06-27
MA43549A (fr) 2021-05-26
JP6933322B2 (ja) 2021-09-08
MX2022000154A (es) 2022-02-21
MX2018008304A (es) 2019-01-24
EP4140988A1 (en) 2023-03-01
AU2017205670B2 (en) 2021-05-20
SG11201804789QA (en) 2018-07-30
PL3397622T3 (pl) 2022-07-04
AU2017205254A1 (en) 2018-08-16
JP7377588B2 (ja) 2023-11-10
UA125377C2 (uk) 2022-03-02
HRP20220673T1 (hr) 2022-07-08
IL259742B (en) 2021-08-31
PT3397622T (pt) 2022-06-15
IL284912B (en) 2022-07-01
AU2017205254B2 (en) 2021-05-20
HUE058871T2 (hu) 2022-09-28
CA3009576A1 (en) 2017-07-13
SI3397622T1 (sl) 2022-07-29
EP3397622B1 (en) 2022-03-09
EA201891095A1 (ru) 2019-01-31
SI3400217T1 (sl) 2022-07-29
JP7169573B2 (ja) 2022-11-11
IL259742A (en) 2018-07-31
PT3400217T (pt) 2022-06-15
DK3397622T3 (en) 2022-06-07
EP3400217A1 (en) 2018-11-14
AU2021218009B2 (en) 2023-06-22
JP2021178858A (ja) 2021-11-18
RS63285B1 (sr) 2022-06-30
ES2916835T3 (es) 2022-07-06
EP3397622A1 (en) 2018-11-07
CA3009573A1 (en) 2017-07-13
IL284912A (en) 2021-08-31
IL260286A (en) 2018-07-31
HRP20220674T1 (hr) 2022-07-22
SG10202009769WA (en) 2020-11-27
EP4144351A1 (en) 2023-03-08
MA43580A (fr) 2021-05-26
RS63286B1 (sr) 2022-06-30

Similar Documents

Publication Publication Date Title
DK3728254T3 (da) Benzylamin-substituerede pyridopyrimidinoner og derivater som sos1-inhibitorer
DK3331894T3 (da) Nicotinamidmononukleotidderivater og anvendelser deraf
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3474996T3 (da) Tågeapparat og anvendelsesmåde
DK3331877T3 (da) Pyrazolpyrimidinderivat og anvendelser deraf
IL250391B (en) Crystalline forms of glutaminase inhibitors
DK3215493T3 (da) Syntese af copanlisib og dihydrochloridsalt deraf
DK3067355T3 (da) Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat
DK3099800T3 (da) Ekspression og oprensning af crm197 og beslægtede proteiner
DK3269809T3 (da) MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3390422T3 (da) Krystalformer af lnt
DK3389669T3 (da) Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3398598T3 (da) Sulfonamidderivat og fremstillingsmetode og anvendelse deraf
DK3143018T3 (da) Carboxamidderivater
DK3512833T3 (da) Heteroarylcarboxamidforbindelser som inhibitorer af ripk2
IL284912A (en) -Valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystalline polymorph thereof
DK3142655T3 (da) Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban
DK3529236T3 (da) Krystalformer af eravacyclin
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3636640T3 (da) Krystal af heterocyclidenacetamidderivat
DK3247711T3 (da) Hidtil ukendte salte og polymorfer af scy-078
DK3418273T3 (da) Derivater af flavagliner